 countries in the global south then it's a non-starter those countries just aren't going to be able to afford it gilead has said it's going to work to make the the prevention tool affordable but they haven't yet set a price and they've also said that they're going to work with generic manufacturers uh so that they can produce a version of it that will be more affordable as well but really that's that's years in the future before we're going to see generic versions of lena capovir and how big a deal would you say this is in terms of i don't know the history of the hiv epidemic